What Changed?
As of January 22, 2026, Swissmedic announced a batch recall of Risperidon-Mepha LA Pulver und Lösungsmittel zur Herstellung einer Suspension zur i.m. Injektion (Risperidon-Mepha LA powder and solvent for suspension for intramuscular injection) affecting batches 4400869, 4400443, 4400446, and 4401766. The recall has been initiated due to quality issues which require the products to be removed from the market. Clinical, quality, and regulatory teams should be aware of this recall as it may impact their day-to-day operations.
Who is Affected?
The recall affects clinical, quality, and regulatory teams working with Risperidon-Mepha LA injection in Switzerland. Any parties holding the specified batches should return the products to their supplier and await further instructions from Swissmedic. Affected parties may also need to perform additional quality control tests on remaining products.
What Actions Did Swissmedic Take?
Swissmedic issued a batch recall order, effective January 22, 2026, requiring the removal of Risperidon-Mepha LA injection batches 4400869, 4400443, 4400446, and 4401766 from the market. The order aims to ensure the quality and safety of products available to the Swiss public. Swissmedic will continue to monitor the situation and update their guidelines accordingly.
What Are the Quality Issues?
Swissmedic has identified quality issues with the affected batches, which necessitated the recall. However, the exact nature of the issues is not specified in the initial announcement. Further details will likely be provided in future updates or through contact with Swissmedic directly.
Frequently Asked Questions
- Q: What should I do if I possess one of the affected batches?
A: Contact your supplier and arrange for the products to be returned.
- Q: Are all Risperidon-Mepha LA injections affected?
A: No, only batches 4400869, 4400443, 4400446, and 4401766 are affected.
Conclusion
Clinical, quality, and regulatory teams should be aware of the batch recall of Risperidon-Mepha LA injection and take necessary actions to ensure products’ quality and safety.
Disclaimer
This article serves as a summary of the Swissmedic announcement. For detailed information, please consult the official Swissmedic resources. This information is not intended to be taken as professional advice; always consult a qualified professional for specific guidance.
For full information about the Swissmedic announcement, see the link below.
https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/qualitaetsmaengel-und-chargenrueckrufe/batch-recalls/chargenrueckruf-risperidon-mepha-la-inj-suspension.html